Sex-specific associations of *Roseburia* with uric acid metabolism and hyperuricemia risk in females

Zhihan Yang^{1#}, Zeng Zhang^{1#}, Mohan Chen², Jin Hu², Yingqi Qiu³, Shijia Lin¹, Xiaolu Zhou¹, Jiachao Zhang^{1,4*}, Shuaiming Jiang^{1*}

 ¹ School of Food Science and Engineering, Key Laboratory of Food Nutrition and Functional Food of Hainan Province, Hainan University, Haikou 570228, Hainan, China
² Bo'ao Yiling Life Care Center, Qionghai 571400, Hainan, China
³ Haikou People's Hospital, Haikou 570228, Hainan, China
⁴ One Health Institute, Hainan University, Haikou 570228, Hainan, China




Zhihan Yang, Zeng Zhang, Mohan Chen, Jin Hu, Yingqi Qiu, Shijia Lin, Xiaolu Zhou, et al. 2025. Sex-specific associations of Roseburia with uric acid metabolism and hyperuricemia risk in females. *iMetaOmics* 2:e70016. <u>https://doi.org/10.1002/imo2.70016</u>



Introduction







Highlights

1. Analysis of 623 population samples suggests microbiological factors behind lower hyperuricemia (HUA) incidence in females.

2. *Roseburia* is a sex-specific genus that may benefit the mitigation of HUA in females.

3. *Roseburia* is positively correlated with estradiol (E2) levels and negatively correlated with uric acid (UA) levels.

4. The xanthine-glycine pathway is positively correlated with the abundance of *Roseburia*, which might contribute to lower UA levels through this pathway.

Sex differences in the effects of HUA on hosts

000




Figure 1. Flowchart of the clinical trial.

Gut microbiota was significantly associated with sex-specific levels of HUA




Figure 2. Differences in the structure of gut microbiota.

Enrichment of bacteria that produce short-chain fatty acids (SCFAs) in the intestinal tract of Female_Health




Figure 3. The Female's gut microbiota differed from that of the male and affects characterization in HUA.

Roseburia as a key biomarker for protection against HUA in females

000




Figure 4. Altered and predictive biomarker of the gut microbiota in female HUA subjects.

Roseburia alleviated HUA in females by upregulating the production of glycine from xanthine






Figure 5. Functional differences in the gut microbiome between diseased and healthy Females.

Mechanism network diagram of sex hormones regulating gut microbes and UA





Spearman's rank correlation

Negative Positive



Figure 6. Mechanisms of *Roseburia* on HUA in females.




Summary

- □ For hyperuricemia (HUA), there is a significant difference between male and female gut microbes and that females have more beneficial genera of gut microbes, which may be one of the reasons why females are less prone to HUA.
- □ In exploring the gender-specific mitigating effects of gut microbes on HUA in females, we identified *Roseburia* as a key genus.
- □ Higher estradiol (E2) levels positively correlated with *Roseburia*, allowing this bacterium to exert a more pronounced effect on reducing uric acid (UA) levels.
- □ These findings not only enhanced our understanding of how sex hormones influence human health by modulating the gut microbiota but also provided a theoretical foundation for developing novel therapeutic strategies for HUA.

Zhihan Yang, Zeng Zhang, Mohan Chen, Jin Hu, Yingqi Qiu, Shijia Lin, Xiaolu Zhou, et al. 2025. Sex-specific associations of Roseburia with uric acid metabolism and hyperuricemia risk in females. *iMetaOmics* 2:e70016. <u>https://doi.org/10.1002/imo2.70016</u>

iMeta: Integrated meta-omics to change the understanding of the biology and environment WILEY



"<u>iMeta</u>" is a Wiley partner journal launched by iMeta Science Society in 2022, first impact factor (IF) **23.8** in 2024, ranking top 107/21973 in world and 2/161 in the microbiology. It aims to publish innovative and high-quality papers with broad and diverse audiences. Its scope is similar to *Nature, Cell, Nature Biotechnology/Methods/Microbiology/Medicine/Food* etc. Its unique features include video abstract, bilingual publication, and social media dissemination, with more than 600,000 followers. Indexed by <u>SCIE</u>, <u>PubMed</u>, <u>Google Scholar</u> etc.

"<u>iMetaOmics</u>" launched in 2024 and *iMetaMed* in 2025, with a target IF>10, and its scope is similar to Nature Communications, Cell Reports, Microbiome, ISME J, Nucleic Acids Research, Briefings in Bioinformatics, etc. All contributes are welcome!

Society: <u>http://www.imeta.science</u>

Publisher: <u>https://wileyonlinelibrary.com/journal/imeta</u>

Submission: <u>https://wiley.atyponrex.com/journal/IMT2</u> <u>https://wiley.atyponrex.com/journal/IMO2</u>





iMetaScience